First, David Brannon couldn’t believe it. Then he couldn’t stand hearing
about it.
Hundreds of people were ill with fungal meningitis they had contracted after
getting pain-killing injections made by a compounding pharmacy in Massachusetts.
Dozens were dead, and the numbers were still rising.
“It’s quite painful to follow, actually,” said the 60-year-old North Carolina
lawyer, recalling a similar outbreak that killed his mother, Mary Virginia
Scyster, in 2002. “It took my mother 66 days to die.”
Scyster was a victim in an outbreak eerily similar to the one now unfolding.
In both, a steroid called methylprednisolone acetate became contaminated with
black fungus during production by compounding pharmacies making large quantities
of the drug.
In 2002, at least seven people got sick and two died
after being injected with a drug made by a South Carolina pharmacy. In the
current outbreak, 419 people have become ill and 30 have
died.
Despite the much higher numbers, nothing much has changed. Mass production of
high-risk medicines by local drug stores continues — not only in South Carolina
but in most other states as well.
“There appear to be no lessons learned from our outbreak in terms of
oversight and regulation of these pharmacies,” said Jeffrey Engel, a 58-year-old
physician who as North Carolina’s state epidemiologist investigated the 2002
incident. All the cases occurred in North Carolina.
His view is shared by the infectious diseases expert who diagnosed Scyster’s
rare infection.
“It’s déjà vu for sure,” said Srilatha Edupuganti, 44, who was at the
University of North Carolina in Chapel Hill and is now at Emory University in
Atlanta. “It’s painful that it’s happening again.”
In the earlier incident, health authorities recalled the drug made by Urgent
Care Pharmacy of Spartanburg, S.C. South Carolina’s Board of Pharmacy found the
pharmacy unsanitary and its sterilization practices inadequate. It suspended the
pharmacist’s license for four years and fined him $10,000. Ultimately, the drug
store closed and lawsuits were filed.
In the current outbreak, officials recalled tainted lots produced by New
England Compounding Center of Framingham, Mass.
“I’m struck that this happened again,” said Engel, who now heads the Council
of State and Territorial Epidemiologists in Atlanta. “There should be a cease
and desist until safety can be guaranteed. Where is the next one happening?”
Traditional compounding involves a pharmacist making a drug only after
getting a prescription with an individual patient’s name on it. Urgent Care
Pharmacy and New England Compounding Center were involved in a different type of
compounding, which involved the small-batch mass production of drugs — including
the riskiest ones, “sterile injectables — by gowned technicians working in clean
rooms with special ventilation.
This type of drug-making in pharmacies continues because 42 states permit
some form of what’s known as “compounding for office use.” That allows
pharmacists to prepare many doses of a drug without patient-specific
prescriptions and to provide them to doctors’ offices and clinics based on those
places’ regular need.
Compounding pharmacies are regulated by state boards of pharmacy and aren’t
held to the same workplace standards and sterility requirements of
pharmaceutical plants. Instead, most follow less strict standards — USP 797 —
set by an organization called the United States Pharmacopeia. While the Food and
Drug Administration can shut down any drug-making activity, in practice it gets
involved with compounding pharmacies only if there are complaints of
contamination or mislabeling — or after a disaster is underway.
The past outbreak
Mary Virginia Scyster and her husband, David, retired to Pinehurst, N.C., not
only for the great golf courses but also because of the town’s reputation for
excellent medical care.
In the spring of 2002, Scyster, who was 77, twisted her back while playing
golf. The pain persisted and she went to a doctor, who injected the area with an
anti-inflammatory steroid. When the drug’s effect wore off, she returned and got
a second injection.
“Within two weeks, she was in bed with a headache that wouldn’t quit,”
recalled her son, David Brannon. “She resisted going to the hospital, and
finally my father just put her in the car and took her. She never came home
again.”
Unbeknownst to her, between the first and second shots, the pain clinic at
Moore Regional Hospital in Pinehurst had turned to a new source for
methylprednisolone when its usual supplier, the drug company Pharmacia,
temporarily stopped making it. Between May 6 and June 5, the pain clinic bought
557 vials of methylprednisolone from Urgent Care Pharmacy.
About 140 miles to the east, in Jacksonville, Johnston Pain Clinic also
turned to Urgent Care, buying 525 vials of methylprednisolone over five
months.
“I couldn’t get what I wanted from anybody else,” recalled anesthesiologist
Scott Johnston, now 53. It was there that Vivian Conrad, a 71-year-old retired
dispatcher for the sheriff’s department with arthritis, got an injection in her
back on June 3.
For both women, weeks or months passed before their infections were fully
diagnosed.
When Scyster didn’t improve after two weeks of therapy for bacterial
meningitis, a second spinal tap was done. It showed microscopic fungus. She was
immediately transferred to Duke University Medical Center, where a world
authority on fungal meningitis worked. There, Exophiala dermatitidis, a species
that sometimes darkens the tile of bathrooms, was identified.
“By the time she got to the hospital she was never out of pain,” recalled
Brannon, her son. “She had a lot of visual hallucinations. It was very
frightening for her. Sometimes she would realize what was going on and sometimes
she wasn’t with us.”
She died on Aug. 25, 2002.
It gets worse
In the meantime, Vivian Conrad, who lived with her husband in the Atlantic
Coast community of Emerald Isle, N.C., was baffling physicians.
“One particular weekend, I remember she was having bad headaches and had had
them all week long,” recalled Conrad’s daughter, Chiquita Prestwood, a
63-year-old bookkeeper in Lenoir, N.C. “I asked where they were and she told me
toward her neck. I said, ‘Mom, that sounds like meningitis. Why don’t you call
your doctor?’ ”
When the weekend was over she did and was admitted to a hospital in Morehead
City on July 8.
Her symptoms, however, resembled those of a stroke, and after eight days she
was discharged home. Two weeks later, she was readmitted. She got no better. On
Aug. 20, she was transferred to a hospital in Greenville, N.C. Fungal meningitis
was diagnosed after that.
“They said her spinal fluid, which should be clear, was almost pure pus,” her
daughter said.
What happened next is unclear. Either with a tip from a Greenville physician
or by the observation of an infectious diseases physician at Duke, the cases of
Scyster, now dead, and Conrad, still alive, were put together. Engel, the state
epidemiologist, was notified and started to investigate.
On Sept. 27, the South Carolina Board of Pharmacy ordered Urgent Care to
close. The pharmacy recalled the methylprednisolone, but it refused to recall
other products, which had been shipped to 11 states. On Nov. 15, the FDA issued
a nationwide alert against using them.
In early December, the Centers for Disease Control
and Prevention described in its newsletter,
Morbidity and Mortality Weekly Report, four cases of
meningitis and one case of joint infection in North Carolina caused
by Exophiala fungus.